Nonetheless, comparable chromosomal ates were received from patients at diagnosis, before any speabnormalities have been reported in other FAB subtypes. [4][5][6][7][8][9][10][11] cific therapy. Mononuclear cells were fractionated using Recently the chromosomal breakpoints resulting in the fusion Ficoll-Hypaque density separation and analyzed immediately gene of CBF␤ (16q) and MYH11 (16p) have been cloned. 12 or viably frozen in liquid nitrogen until use. All samples were The human CBF␤ has a high degree of homology with the part of diagnostic and clinical follow-up procedures. murine CBF␤ gene. 13 Several studies suggest that the CBF␤ protein forms a complex with the DNA-binding protein CBF␣ subunit and contributes to the transcription, mostly of tissueCytogenetic study specific genes.
Patients
inv (16) Informed consent was obtained from all patients before being included in the study. Bone marrow (BM) or peripheral blood Introduction (PB) samples were obtained from 70 patients: 11 M4Eo, 31 M4, 19 M5, one M0, two M1, three M2, one M7, one secondAcute myelomonocytic leukemia with bone marrow eosinoary AML and one biphenotypic leukemia. Diagnosis was philia (AML-M4Eo) is a distinct subtype of acute myeloid established by clinical and cytological criteria, based on the leukemia (AML), strongly correlated with rearrangements of FAB classification. 2, 18, 19 In particular, M7 diagnosis was based chromosome 16 of good prognostic significance, 1 on both cytological and immunophenotype criteria. 19 Hepmostly inv(16)(p13q22) but also t(16;16)(p13;q22) and arinized periperal blood samples and/or bone marrow aspirdel(16)(q22). 2, 3 Nonetheless, comparable chromosomal ates were received from patients at diagnosis, before any speabnormalities have been reported in other FAB subtypes. [4] [5] [6] [7] [8] [9] [10] [11] cific therapy. Mononuclear cells were fractionated using Recently the chromosomal breakpoints resulting in the fusion Ficoll-Hypaque density separation and analyzed immediately gene of CBF␤ (16q) and MYH11 (16p) have been cloned. 12 or viably frozen in liquid nitrogen until use. All samples were The human CBF␤ has a high degree of homology with the part of diagnostic and clinical follow-up procedures. murine CBF␤ gene. 13 Several studies suggest that the CBF␤ protein forms a complex with the DNA-binding protein CBF␣ subunit and contributes to the transcription, mostly of tissueCytogenetic study specific genes. 12 The human smooth muscle heavy chain MYH11, with its periodic distribution of hydrophobic/charged Peripheral blood samples and/or bone marrow cells were culresidues and its high potential for ␣-helical formation, 14, 15 tured for 24-72 h, and high resolution chromosomal analysis probably plays a role in the dimerization of the myosin thick was performed according to a previously described profilament with other molecules. Although both CBF␤ and cedure. 20 At least 20 metaphase cells, when possible, were MYH11 are consistently involved in inv (16) , their respective examined. Karyotypes were described according to the Interrole in the pathogenesis of the disease is far from clear. 16 national System for Human Cytogenetic Nomenclature. amplification reactions, 2.5 mg of RNA was used as the temtinylated oligoprobe, and the membranes were incubated overnight at 42°C. After removal of the hybridization buffer, plate.
the streptavidine-peroxidase conjugate (Cetus, Roissy, France, 1/300 final dilution) was incubated at 55°C for 1 h in 5 × SSC, 0.5% SDS. The washing conditions were: 20 min at room tem-
RT-PCR amplification
perature, then 20 min at 55°C in 2 × SSC, 0.1% SDS, followed by 20 min at RT 2 × phosphate-buffered saline (PBS). DetecThis was performed as already described 22 with slight modifications. Briefly, for RT, 2.5 g of total RNA was reversetion of hybridization product was performed with the chemiluminescent assay ECL kit (Amersham) and autoradiographed transcribed with MMLV Superscript reverse transcriptase and random hexamers (Life Science). For PCR, 5 l of this cDNA on XAR film (Kodak, New Haven, CT, USA) with an intensifier screen (Kodak) at room temperature, usually for 1-3 min (short was used as the target in a total volume of 50 l containing 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl pH 8.5, 200 mM exposure) to 2 h (long exposure).
Patients' samples were tested several times, following the each of dNTP, 1 mM of each primer and 1.25 U of Taq polymerase (Perkin-Elmer, Roissy, France). The amplification was precautions defined 24 to avoid PCR-related false positive. Furthermore, when enough material was available, the RNA from performed in a 9600 DNA thermal cycler (Perkin-Elmer); first cycle denaturation at 94°C for 3 min, then annealing at 58°C the positive cases was amplified, following our RT-PCR conditions but with the omission of the reverse transcriptase. This for 30 s, extension at 72°C for 30 s, and then denaturation at 94°C for 30 s for 34 cycles, terminating with 10 min at 72°C.
control (RT negative control) allowed any cross-contamination of the RNA samples to be detected.
Primers and oligoprobes Positive controls and dilution experiments
For detection of the housekeeping gene abl, the following primers were used: the 5′ oligonucleotide 5′-GGATo assess the sensitivity of RT-PCR with C1/M1 primers, 1 mg of total RNA isolated from the ME-1 cell line (kindly provided CAGGCCCATGGTACCAGGAG-3′ and the 3′ oligonucleotide 5′-CTCAGCCAGTAGCATCTGAC-3′. 23 The oligonucleotides by Dr K Yanagisawa, First Department of Internal Medicine, School of Medicine, Ehime University, Japan), 25 which used for MYH11/CBF␤ fusion detection are described in Table 1 . For screening at diagnosis, C1/M1, C1/M2 and expresses the 'A-type' transcript, was serially diluted in RNA extracted from the TF1 cell line 26 which has no CBF␤/MYH11 C1/M3 primers were used together with a P1b hybridization probe. In some cases, C4/M0 primers were used together with fusion transcript. The resulting cDNA was then submitted to standard PCR amplification. Type C and D PCR products a P3b probe. The localization of these primers and probes are indicated in a schematic representation of an inverted 16 (kindly provided by Dr JM Cayuela, Laboratoire Central d'Hématologie, Hô pital Saint Louis, Paris, France) were used chromosome ( Figure 1a) .
as positive controls for C1/M2 and C1/M3 amplifications.
PCR product analysis Sequence analysis
The quality of the RNA and the RT step were checked by the amplification of the ubiquitously expressed abl gene. The Sequence analysis of the PCR product was performed according to a previously described fluorescent method. 27 CBF␤/MYH11 fusion PCR products, after electrophoresis on 2.5% agarose gel, were transferred onto a nylon membrane (Hybond N+, Amersham). The hybridization was performed with an internal biotinylated oligoprobe (P1b) which controls Results the PCR product specificity and increases the sensitivity. The membranes were pre-hybridized for 4 h at 42°C in 6 × SSC
Patients' characteristics
(1 × SSC = 15 mmol/l sodium citrate, 150 mmol/l sodium chloride), 0.5% sodium dodecyl sulfate (SDS), 1 × Denhardt's
The 70 patients studied were classified without prior knowledge of RT-PCR or karyotype findings. Karyotype and RT-PCR solution, and 200 g/l salmon sperm. The buffer was then changed for a new one containing an additional 1 pmol/l bioanalysis of CBF␤/MYH11 fusion transcripts were done under the same conditions for all patients. Of these 70 patients, 14
Detection of CBF␤/MYH11 fusion transcripts by RT-PCR had chromosome 16 abnormalities and/or CBF␤/MYH11 fusions transcripts, of which the biological and clinical
The C1/M1, C1/M2 and C1/M3 set of primers, and hybridizcharacteristics at diagnosis are summarized in Table 2 . There ation with P1b probe, were used for screening at initial diagwere seven men and seven women, the median age at diagnosis. The sensitivity of our RT-PCR amplification reached in nosis was 38 years (range 19-74). Ten out of the 14 patients all cases at least one cellular equivalent out of 10 4 and posihad an M4Eo FAB subtype. There were also three M5 and one tive controls were used for each experiment, thus avoiding M7 AML. Regarding the three M5 AML (patient Nos 7, 11 and false negative results (data not shown). Ten out of the 14 13), characteristic eosinophil abnormalities were also patients had the classic 'A type' 8 424-bp PCR product when observed, but the weak granulocytic differentiation (Ͻ10%) using the C1/M1 set of primers (Figure 1b) . did not allow M4 classification according to FAB criteria. One
Despite the presence of typical inv (16) , no CBF␤/MYH11 patient (No. 8) with a low percentage of eosinophil precursors fusion product was detected for patient No. 3 (Figure 1b ), but characteristic abnormalities was classified as M4Eo. The although a clear signal was amplified for abl (Figure 1c ), dem-M7 diagnosis was based on both cytological and immunoonstrating the quality of the RNA and RT product. phenotype criteria. 19 Interestingly, absolutely no eosinophils For patient No. 1, the use of C1 and M1 primers obtained were detected in the bone marrow of this patient. The median a 573-bp product instead of the classical 'A-type' (Figure 1b ) bone marrow eosinophil precursor count was 13% (range 0-while the use of the C4/M0 set of primers led to a 257-bp 42). The typical inv(16)(p13;q22) translocation was observed product (data not shown). RT-PCR analysis using the M3 in 12 patients and t(16;16)(p13;q22) in one patient. Trisomy primer, which was located from nucleotide 1260 to 1282 of 22, the most frequent abnormality associated with inv(16), 28, 29 MYH11, failed to amplify any product (data not shown). 
Discussion
analysis of CBF␤/MYH11 fusion transcripts in AML patients bearing inv (16) or equivalent abnormalities, with or without M4Eo subtype. [8] [9] [10] [11] [12] 30 Detection of CBF␤/MYH11 fusion tranBecause of the high frequency of chromosome 16 abnormalities in these FAB subtypes, our study mainly focused on M4 script has been reported to represent 10% of M4 patients without eosinophil abnormalities and without chromosome 16 and M5 AML. 4 Already several publications have reported the alterations. 5 In contrast, our data, like others in a smaller series myelodysplastic syndromes [33] [34] [35] or CML blast crisis [36] [37] [38] [39] has to be analyzed in a large series. suggest that this is a rare event: less than 5% if all the M4 cases without eosinophilia reported today, including our paper, are
In our study, in only one case was CBF␤/MYH11 transcript not detected despite inv (16) . Such cases have already been combined. 5, 31 According to the FAB classification, 2 in M4Eo AML typical abnormal bone marrow eosinophils (usually 5% described 8,10,31 and have raised many hypotheses such as the use of inadequate primers, rearrangement of CBF␤ or MYH11 or more of nonerythroid cells) are observed, such as cells with a single unsegmented nucleus containing large, irregular, to a different gene or even the involvement of two different genes. This patient will be further analyzed by chromosomal immature, dark purple rather than bluish granules admixed with normal appearing ones. Unfortunately, most of the publifluorescent in situ hybridization (FISH) 40 and Southern blotting. 41 Another patient with typical M4Eo had no cytogenetic cations did not give detailed information about the eosinophil cell population in the AML cases without eosinophilia. [8] [9] [10] 31 abnormalities (but only four metaphases were obtained) or detectable CBF␤/MYH11 transcript, and will also require In our study, three M5 AML expressed CBF␤/MYH11 fusion transcript and had eosinophils sharing the classical abnormalifurther investigation. At least 11 different CBF␤/MYH11 fusion transcripts have ties observed in M4Eo. Our data suggest a correlation between qualitiative abnormalities of the eosinophil differentiation and already been described. 11, 16 In the 14 patients reported here, 10 had the common 'A-type' transcript.
8 This is the second presence of CBF␤/MYH11 fusion transcript, rather than with a particular FAB subtype. It has recently been demonstrated time that the rare transcript found in patient Nos 4 and 14, corresponding to type 3 of Shurtleff et al 10 or 'G-type' in the that the abnormal eosinophils in M4Eo carry the specific pericentric inv (16) ; 32 the hypothesis that abnormal eosinophils in review of Liu et al 16 has been reported. One of our patients has an M7 FAB subtype and presented a t(16;16)(p13;q22), non-M4Eo AML also belong to the leukemic population has to be further tested. Systematic AML screening with both cytowhile the second one had M4Eo with chromosome 8 trisomy but no cytogenetic chromosome 16 abnormalities. We furthergenetic and molecular techniques is clearly a poor costefficiency strategy. As a consequence, we would recommend more describe here a novel chimerical transcript in a typical M4Eo/inv(16) patient. Although the fusion of CBF␤ nucleotide the RT-PCR screening for CBF␤/MYH11 fusion transcript in AML patients to be oriented by the morphological features, ie 495 to MYH11 nucleotide 994 has already been described as 'E-type', 11 it is in our case associated with an as yet undethe presence of abnormal eosinophils. The presence of the CBF␤/MYH11 fusion transcript might define a subtype of scribed 785-bp in-frame deletion on MYH11. This deletion involves nucleotides 1157-1942 or 1166-1951; we cannot AML. Whether this molecular definition is relevant in AML,
